What the March 2026 NIH Grants Policy Statement Revision Means for Your Application

Why the NIHGPS Matters More Than Most Researchers Realize

The NIH Grants Policy Statement is the closest thing NIH has to a governing document for its extramural research enterprise. It defines how grant funds can be spent, what obligations recipients take on, and what NIH can and can't require of grantees. It's also the document that most PIs never open until something goes wrong.

The March 2026 revision, published as NOT-OD-26-057, is effective for all NIH grants and cooperative agreements as of its release date. It incorporates policy changes, statutory requirements, and regulatory clarifications that accumulated between April 2024 and March 2026. NIH's own summary of significant changes identifies six areas where something materially different now applies to your grant.

Unlike a lot of policy documents, several of these changes affect decisions you'd make during application planning, not just after an award arrives. The foreign subaward change, in particular, has already caused confusion among teams with established international collaborations. If you have foreign partners, support trainees on NRSA mechanisms, or run animal studies, it's worth knowing what changed before you write your next budget.

Foreign Subawards Are No Longer Recognized

Perhaps the most operationally significant change in the March 2026 revision is this: NIH no longer recognizes foreign subawards. Under the previous NIHGPS, a domestic grantee could issue a subaward to a foreign entity — a university abroad, an international research institute — and that arrangement would be treated as a legitimate subrecipient relationship. The foreign organization would receive its own budget allocation, carry its own indirect costs, and file its own progress reports under the domestic award.

That framework is gone. The March 2026 revision removes the policy pathway for foreign subawards entirely. Institutions that haven't adjusted their sponsored programs templates may not realize the change happened yet.

If you're planning a new application with meaningful foreign collaboration, budget planning needs to reflect this reality now. Setting up a foreign collaborator as a subawardee and expecting NIH to approve it during review is no longer a viable approach. Your sponsored programs office needs to be in this conversation before the application goes in, and your program officer is a reasonable first call if you're uncertain which restructuring path your specific institute prefers.

Budget Changes That Work in Your Favor

Two changes in the March 2026 revision extend allowable costs in ways that are genuinely useful, and both are things that researchers have been quietly absorbing on their own for years without clear policy authority.

First: childcare costs are now explicitly allowable for full-time predoctoral and postdoctoral trainees supported by National Research Service Award mechanisms. This is a change to the policy statement itself, not a new grant type or a supplemental program. If you're a PI training predocs or postdocs through T32 or individual F-series awards, and those trainees are working full-time, childcare is now a legitimate budget line. This change reflects a broader effort across federal agencies to reduce attrition among early-career researchers who are also caregivers.

Second: costs associated with the disposition of research animals are now explicitly allowable, including adoption programs and retirement to sanctuary facilities. Researchers using animal models have sometimes absorbed end-of-life or retirement costs informally because the allowability was ambiguous. The March 2026 revision ends that ambiguity. You can budget for adoption, retirement, or standard euthanasia from the start of a project period rather than scrambling to cover it at the end. If your lab runs ongoing animal studies, this change is worth building into your next budget template.

Indirect Costs and the 45 CFR 75 vs. 2 CFR 200 Question

There has been sustained uncertainty in the sponsored programs world about whether NIH would shift its indirect cost framework from 45 CFR Part 75 to the updated thresholds in 2 CFR Part 200, the Uniform Guidance. The March 2026 NIHGPS makes NIH's current position clear: indirect costs continue to be governed by 45 CFR 75. NIH will not apply the updated thresholds from 2 CFR Part 200 at this time.

In practical terms, this means your institution's negotiated Facilities and Administrative rate continues to apply as negotiated. There's no windfall and no cut from a regulatory shift. Institutions that built their rates under the 45 CFR 75 framework stay on that framework. Sponsored programs offices across the country have generally welcomed this continuity — a mid-cycle rate change would have created significant administrative burden for both institutions and NIH grants management specialists.

For applicants, the takeaway is simple: don't expect your indirect cost rate to change because of this NIHGPS revision. The longer-term question of whether and when NIH transitions to 2 CFR Part 200 thresholds remains open. If your institution has questions about that trajectory or about F&A rate negotiations, those conversations happen with your cognizant federal agency separately from the policy statement.

Conference Grants and Other Clarifications

A smaller but practically useful change: the March 2026 revision removes language that required a Letter of Intent for conference grants. Mechanisms like the R13 and U13 previously had ambiguity in the NIHGPS about when LOIs were required at the policy level. Removing that blanket language means the requirement now lives entirely at the level of the individual Notice of Funding Opportunity. If your specific NOFO asks for an LOI, file one. If it doesn't, you don't need one. Don't assume either direction from past habit — check the NOFO.

The revision also reflects statutory changes affecting research involving human fetal tissue. NIH funds are no longer permissible for research using human fetal tissue derived from elective abortions. Researchers in fields where HFT has historically been part of the work should review ongoing and planned studies with their institutional compliance and IRB teams. This applies to new applications and to currently funded awards going forward.

Several other sections of the NIHGPS received clarifying edits without substantive policy changes: language updates around indirect cost categories, minor revisions to Other Support reporting guidance, and administrative cleanups to text that had become inconsistent across sections of the document. If a specific provision was generating confusion at your institution, the NIH "Summary of Significant Changes" document is faster to read than the full NIHGPS.

What to Do Before Your Next Submission

The March 2026 NIHGPS is effective as of its publication date. For most changes, that means prospective application: what you do from March 2026 forward is governed by the new policy. The foreign subaward change is the exception worth checking against your current portfolio now, not only at your next submission cycle.

The NIHGPS revision isn't a headline policy event. It doesn't restructure review criteria, alter the submission calendar, or shift funding levels at any institute. But it's exactly the kind of document where not knowing what changed eventually costs someone a budget modification request, a compliance flag during a site visit, or a strained collaborator relationship that a fifteen-minute conversation with sponsored programs could have prevented. The full text and the Significant Changes summary are both at grants.nih.gov under Policy and Compliance.

Frequently Asked Questions